When Should You Get Your First DXA Scan? Current Guidelines Explained

Why Screening Matters

Osteoporosis is often called a "silent disease" because bone loss occurs without symptoms until a fracture happens. Unlike conditions such as hypertension or high cholesterol, where blood tests or routine measurements can detect the problem early, bone loss is invisible in everyday life. You cannot feel your bone density declining. The first clinical sign of osteoporosis for many people is a fragility fracture — a fracture from a fall from standing height or less, or even from a minor stress that would not injure healthy bone.

This is why screening with DXA (dual-energy X-ray absorptiometry) exists: to identify individuals with low bone density before a fracture occurs, so that preventive treatment can be initiated. But screening everyone, at every age, is neither practical nor supported by evidence. Guidelines exist to identify the populations where screening provides the most benefit relative to cost and potential harms.

The Major Guidelines

US Preventive Services Task Force (USPSTF)

The USPSTF is an independent panel of evidence-based clinicians that makes screening recommendations for the US population. Their osteoporosis screening recommendations, reaffirmed in 2018, are among the most widely cited:

• Women aged 65 and older: Screen with DXA. This is a Grade B recommendation, meaning there is moderate certainty of moderate net benefit. No specific screening interval is recommended — the evidence was insufficient to determine optimal rescreening frequency.
• Postmenopausal women under 65 at increased risk: Screen with DXA. The USPSTF suggests using a clinical risk assessment tool (such as FRAX, the Osteoporosis Self-Assessment Tool, or others) to identify women whose fracture risk is equal to or exceeds that of a 65-year-old White woman without additional risk factors.
• Men: The USPSTF concluded that the evidence was insufficient (Grade I — insufficient evidence) to recommend for or against routine osteoporosis screening in men. This does not mean men should not be screened — it means the evidence base for population-level male screening is not yet robust enough for a recommendation.

International Society for Clinical Densitometry (ISCD)

The ISCD provides more detailed guidance on who should receive DXA testing. Their indications for bone density testing include:

• Women aged 65 and older
• Men aged 70 and older
• Postmenopausal women under 65 and men aged 50-69 with clinical risk factors for fracture
• Adults who have a fragility fracture (to confirm diagnosis and guide treatment)
• Adults with a condition or taking a medication associated with low bone mass or bone loss (e.g., glucocorticoid therapy, hyperparathyroidism, aromatase inhibitor or androgen deprivation therapy)
• Anyone being considered for pharmacological treatment for osteoporosis
• Anyone being treated for osteoporosis, to monitor response
• Anyone not receiving therapy in whom evidence of bone loss would lead to treatment
• Women discontinuing estrogen therapy who are at risk for osteoporosis

Endocrine Society

The Endocrine Society's clinical practice guidelines for osteoporosis in men specifically recommend DXA screening for men aged 70 and older and for men aged 50-69 with risk factors such as low body weight, prior fragility fracture, glucocorticoid use, or hypogonadism.

American Association of Clinical Endocrinology (AACE)

AACE recommends DXA for all postmenopausal women aged 65 and older, postmenopausal women of any age with risk factors, and men aged 70 and older or men over 50 with risk factors.

Risk Factors That Should Prompt Earlier Screening

Across guidelines, there is consistent agreement that certain risk factors should prompt DXA screening at younger ages than the general population thresholds. These include:

• Prior fragility fracture: Any fracture from a standing height or less after age 50 warrants DXA testing to establish whether osteoporosis is present.
• Chronic glucocorticoid use: Defined as 5 mg or more of prednisone equivalent daily for 3 months or more. The American College of Rheumatology recommends baseline DXA within 6 months of starting chronic glucocorticoid therapy, regardless of age.
• Premature menopause or early estrogen deficiency: Women who experience menopause before age 45 (natural or surgical) are at increased risk for early bone loss and should discuss DXA timing with their clinician.
• Conditions causing secondary osteoporosis: This includes hyperparathyroidism, hyperthyroidism, celiac disease, inflammatory bowel disease, type 1 diabetes, rheumatoid arthritis, chronic kidney disease, and other malabsorptive or inflammatory conditions.
• Medications that affect bone: Beyond glucocorticoids, aromatase inhibitors (used in breast cancer treatment), androgen deprivation therapy (used in prostate cancer), some anticonvulsants, and long-term proton pump inhibitor use have been associated with bone loss.
• Low body weight: A body weight under approximately 127 pounds (57.7 kg) is a risk factor for low bone density.
• Parental history of hip fracture
• Current smoking
• Excessive alcohol intake: Three or more drinks per day

Common Questions About DXA Screening

Why Not Screen Everyone at 50?

Screening recommendations balance the benefit of early detection against the costs (financial cost of testing, downstream costs of treating low-risk individuals, and potential harms of labeling healthy individuals as "diseased"). For most 50-year-old women with no risk factors, the probability of osteoporosis is low, and the number needed to screen to prevent one fracture is very large. Screening at 65 provides a better yield in terms of identifying individuals who will actually benefit from intervention.

That said, screening earlier than 65 is appropriate for women with risk factors, which is why the USPSTF and other guidelines explicitly recommend earlier screening in at-risk populations.

How Often Should DXA Be Repeated?

There is no single evidence-based answer to this question, and guidelines are somewhat vague on the topic. A study published in The New England Journal of Medicine by Gourlay and colleagues followed nearly 5,000 women aged 67 and older who had normal or mildly reduced bone density at baseline. They found that the estimated time for 10% of women to develop osteoporosis varied dramatically based on initial T-score:

• Normal bone density (T-score -1.0 or above): Approximately 15 years
• Mild osteopenia (T-score -1.01 to -1.49): Approximately 5 years
• Moderate osteopenia (T-score -1.50 to -1.99): Approximately 3 years
• Advanced osteopenia (T-score -2.00 to -2.49): Approximately 1 year

This suggests that rescreening intervals should be tailored to the individual's baseline bone density and risk profile rather than applied uniformly. Women with normal bone density at 65 may reasonably wait 10-15 years before repeating the scan, while women with moderate osteopenia may benefit from more frequent monitoring.

Does Insurance Cover DXA Screening?

In the United States, Medicare covers DXA screening every 24 months for individuals who meet certain criteria, including postmenopausal women, individuals on glucocorticoid therapy, individuals with primary hyperparathyroidism, and individuals being monitored for osteoporosis treatment response. Many commercial insurance plans follow similar coverage criteria. However, coverage can vary, and it is worth confirming with your insurance provider before scheduling a scan.

What About Peripheral DXA or Ultrasound Screening?

Peripheral DXA devices (measuring bone density at the heel, wrist, or finger) and quantitative ultrasound (QUS) devices are sometimes used in screening settings, particularly at health fairs or pharmacy screenings. While these technologies can identify individuals with low bone density, they are not interchangeable with central DXA (spine and hip) for diagnosis or treatment decisions. The ISCD states that if a peripheral measurement suggests low bone density, confirmation with a central DXA is recommended before making treatment decisions.

What To Do With Your Results

A DXA scan is not an end in itself — it is a starting point for a clinical conversation. If your results show normal bone density, the next step is to determine an appropriate interval for rescreening based on your risk profile. If your results show osteopenia, a FRAX assessment can help determine whether your 10-year fracture risk warrants treatment or continued monitoring. If your results show osteoporosis, a discussion about pharmacological treatment options, calcium and vitamin D intake, exercise, and fall prevention should follow.

The most important step is to have the conversation. Ask your clinician whether DXA screening is appropriate for you based on your age, sex, medical history, and risk factors. If you have already had a DXA scan, ask about the significance of your results and when rescreening should occur. Screening is only useful if the results lead to informed clinical action.